Canaccord maintains its Hold rating and $42 target on St Jude Medical, Inc. STJ as Quadra gains FDA approval and Riata is updated in doctor letters.
Canaccord says, “We continue to model '11 and '12 CRM sales growth of 1% and 2%, respectively, which would constrain overall top-line growth as CRM is >50% of sales. That said, STJ has a robust pipeline (e.g., CardioMems, TAVI); ergo successful, on-time launches could improve top-line growth relative to our current targets in out years.”
STJ closed at $35.69 per share on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in